Source: Korea Biomedical Review

PharmAbcine: PharmAbcine to be delisted from Kosdaq amid financial and operational struggles

PharmAbcine announced that the Kosdaq Market Committee decided to delist its stock on Wednesday.PharmAbcine can appeal the decision within 15 business days of the date of notification. If no appeal is made, the delisting process will proceed after the appeal period expires.If an appeal is lodged, th

Read full article »
Est. Annual Revenue
$5.0-25M
Est. Employees
25-100
Dr. Jin San YOO's photo - CEO of PharmAbcine

CEO

Dr. Jin San YOO

CEO Approval Rating

68/100

Read more